| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 3,090 | 891 | 1,033 | 1,185 | 1,057 |
| Sales Growth | +246.82% | -13.75% | -12.86% | +12.17% | -54.08% |
| Net Income | -8,540 | -11,885 | -13,906 | -14,016 | -6,535 |
| Net Income Growth | +28.14% | +14.53% | +0.79% | -114.49% | -7.06% |
Polarean Imaging Plc (POLX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Polarean Imaging PLC designs and manufactures medical drug-device combination companies operating in the high-resolution medical imaging market. Its only operating segment is the development and commercialization of gas polariser devices and ancillary instruments. Geographically, it derives the majority of its revenue from the United States of America and also has a presence in Canada and the United Kingdom. The company generates revenue from products and services such as Polarisers, Parts and Upgrades, Service, and other revenue. Its product portfolio includes 9820 129Xe Hyperpolarizer, 9800 129Xe Hyperpolarizer, Polarean 3777 129Xe Hyperpolarizer Upgrade Module, Polarean 2881 Polarization Measurement Station, and others.
Fiscal Year End Date: 12/31